Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Amortizatization of Intangibles (2025)

Soleno Therapeutics (SLNO) has disclosed Amortizatization of Intangibles for 2 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Amortizatization of Intangibles changed N/A to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.5 million, a N/A change, with the full-year FY2025 number at $3.5 million, down 28.15% from a year prior.
  • Amortizatization of Intangibles was $1.2 million for Q4 2025 at Soleno Therapeutics, up from $371000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $1.2 million in Q4 2025 to a low of $371000.0 in Q3 2025.